TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

What are the pros and cons of bispecific antibodies for multiple myeloma?

Featured:

Roberto MinaRoberto MinaAndrzej Jakubowiak

Jul 29, 2022

Learning objective: After reading this article, learners will be able to cite a new clinical development in multiple myeloma.


During the ASCO 2022 Congress, the Multiple Myeloma Hub was pleased to speak to Roberto Mina, University of Turin, Turin, IT, and Andrzej J. Jakubowiak, The University of Chicago, Chicago, US. We asked, What are the pros and cons of bispecific antibodies for multiple myeloma? 

What are the pros and cons of bispecific antibodies for multiple myeloma?

Mina and Jakubowiak discuss the MajesTEC-1 and MagnetisMM-1 trials, the efficacy and response rates of bispecific antibodies, and the challenges of using bispecific antibodies, such as infection risk. They also compare bispecific antibodies to CAR T-cell therapies and talk about the sequencing of therapies in myeloma treatment.

This educational resource is supported through funds from pharmaceutical companies; a full list of our supporters can be found at https://multiplemyelomahub.com/. All content is developed independently by SES in collaboration with the faculty. The funders are allowed no influence on the content of this resource.

 

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content